Clinical Analysis of 34 Patients with Nasal Cavity T-cell Non-Hodgkin Lymphoma

陈泽程,庞丹梅,叶锡乡,白永红,唐溢聪,梁剑苗,招丽蓉,黄慧强
DOI: https://doi.org/10.3760/cma.j.issn.1009-9921.2006.01.014
2006-01-01
Abstract:Objective To investigate the clinical feature and treatment options of primary nasal cavity T-cell non-Hodgkin lymphoma(NHL). Methods From January 1997 to December 2001,34 patients primary nasal cavity T-cell NHL were treated in our hospital. Twenty three patients were treated by chemotherapy plus radiotherapy,9 patients chemotherapy alone,two patients had no treatment. All patients received chemotherapy of CHOP regimen. Results The response rates(RR) of chemotherapy alone were 44.4 %, complete remission (CR) rates were 22.2 %; the response rates of chemotherapy plus radiotherapy were 100.0 %, CR rates were 86.9 %. The 1, 3, 5 year overall survival rates were 52.9 %, 41.2 % and 18.3 %, respectively. The 5 year overall survival rates of chemotherapy plus radiotherapy were higher than chemotherapy alone; The survival of the patients with localized disease was longer than the disseminated. Conclusion Treatment outcomes of nasal cavity T-cell non-Hodgkin lymphoma was unsatisfactory; Effectivenes of CHOP was limited; Combined chemotherapy with radiotherapy may improve survival. Further investigation is warranted.
What problem does this paper attempt to address?